

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7041925

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>SEQUENCE:</b>	1

## CONVEYING PARTY DATA

Name	Execution Date
BAUSCH HEALTH IRELAND LIMITED	11/23/2021
BAUSCH+LOMB IRELAND LIMITED	11/23/2021
SALIX PHARMACEUTICALS, INC.	11/23/2021
BAUSCH & LOMB INCORPORATED	11/23/2021
BAUSCH HEALTH US, LLC	11/23/2021
SOLTA MEDICAL, INC.	11/23/2021
SOLTA MEDICAL IRELAND LIMITED	11/23/2021

## RECEIVING PARTY DATA

<b>Name:</b>	BARCLAYS BANK PLC, AS COLLATERAL AGENT
<b>Street Address:</b>	745 SEVENTH AVENUE
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10019

## PROPERTY NUMBERS Total: 13

Property Type	Number
Application Number:	17207222
Application Number:	17489939
Application Number:	63243823
Application Number:	63239246
Application Number:	17462962
Application Number:	63239343
Application Number:	63239344
Application Number:	17398556
Application Number:	17397496
Application Number:	63226614
Application Number:	29788730
Application Number:	17366871
Application Number:	17365353

PATENT

**CORRESPONDENCE DATA****Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 800-494-5225  
**Email:** ipteam@coagencyglobal.com  
**Correspondent Name:** JAY DASILVA  
**Address Line 1:** 1025 CONNECTICUT AVE., NW, STE. 712  
**Address Line 2:** COGENCY GLOBAL INC.  
**Address Line 4:** WASHINGTON, D.C. 20036

<b>ATTORNEY DOCKET NUMBER:</b>	1529686 PAT A
--------------------------------	---------------

<b>NAME OF SUBMITTER:</b>	ASHLEY KIM
---------------------------	------------

<b>SIGNATURE:</b>	/Ashley Kim/
-------------------	--------------

<b>DATE SIGNED:</b>	11/24/2021
---------------------	------------

**Total Attachments: 9**

source=A - Patent IPSA - Q3 2021 (Barclays)#page3.tif  
source=A - Patent IPSA - Q3 2021 (Barclays)#page4.tif  
source=A - Patent IPSA - Q3 2021 (Barclays)#page5.tif  
source=A - Patent IPSA - Q3 2021 (Barclays)#page6.tif  
source=A - Patent IPSA - Q3 2021 (Barclays)#page7.tif  
source=A - Patent IPSA - Q3 2021 (Barclays)#page8.tif  
source=A - Patent IPSA - Q3 2021 (Barclays)#page9.tif  
source=A - Patent IPSA - Q3 2021 (Barclays)#page10.tif  
source=A - Patent IPSA - Q3 2021 (Barclays)#page11.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of November 23, 2021, (this “**Agreement**”), among the entities identified as grantors on the signature pages hereto (collectively, the “**Grantors**”) and Barclays Bank PLC (“**Barclays**”), as collateral agent (in such capacity, the “**Collateral Agent**”) for the Secured Parties.

Reference is made to that certain Third Amended and Restated Pledge and Security Agreement, dated as of June 1, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time and in effect on the date hereof, the “**Security Agreement**”), among the Loan Parties party thereto and the Collateral Agent. The Lenders (as defined below) have extended credit to the Borrowers subject to the terms and conditions set forth in that certain Fourth Amended and Restated Credit and Guaranty Agreement dated as of June 1, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified and in effect on the date hereof, the “**Credit Agreement**”), by and among Bausch Health Companies, Inc. (formerly known as Valeant Pharmaceuticals International, Inc., the “**Parent**”), Bausch Health Americas, Inc. (formerly known as Valeant Pharmaceuticals International, and, together with the Parent, the “**Borrowers**”), certain subsidiaries of the Parent, as subsidiary guarantors, the Lenders from time to time party thereto (the “**Lenders**”), and Barclays, in its capacities as the Swingline Lender and as Administrative Agent for the Lenders. Consistent with the requirements set forth in Sections 4.01 and 5.12 of the Credit Agreement and Section 4.3 of the Security Agreement, the parties hereto agree as follows:

SECTION 1. **Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreement.

SECTION 2. **Grant of Security Interest.** As security for the prompt and complete payment or performance, as the case may be, in full of the Secured Obligations, each Grantor, pursuant to the Security Agreement, did and hereby does pledge, collaterally assign, mortgage, transfer and grant to the Collateral Agent, its successors and permitted assigns, on behalf of and for the ratable benefit of the Secured Parties, a continuing security interest in all of its right, title or interest in, to or under all of the following assets, whether now owned or at any time hereafter acquired by or arising in favor of such Grantor and regardless of where located (the Trademark Collateral, Patent Collateral and Copyright Collateral, each as defined below, collectively, the “**IP Collateral**”):

A. The “**Trademark Collateral**”, defined as set forth in paragraphs (1) through (4) directly below:

1. all Trademarks, including those Trademark registrations and registration applications in the United States Patent and Trademark Office listed on Schedule I hereto;
2. all goodwill associated with or symbolized by the Trademarks;
3. the right to sue third parties for past, present and future infringements, dilutions or violations of any Trademark; and
4. all proceeds of and rights associated with the foregoing;

B. The “**Patent Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Patents, including those Patent registrations and pending applications in the United States Patent and Trademark Office listed on Schedule II hereto;

2. the right to sue third parties for past, present and future infringements of any Patent; and
3. all proceeds of and any right associated with the foregoing; and

C. The “**Copyright Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Copyrights, including those Copyright registrations and pending applications for registration in the United States Copyright Office listed on Schedule III;
2. the right to sue third parties for past, present and future infringements of any Copyright, and
3. all proceeds of and rights associated with the foregoing;

Notwithstanding anything to the contrary in (A) through (C) above, this Agreement shall not constitute a grant of a security interest in any Excluded Assets, including any “intent-to-use” Trademark applications prior to the filing and acceptance of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto.


**SECTION 3. Security Agreement.** The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.

**SECTION 4. Governing Law.** This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

**SECTION 5. Counterparts.** This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Agreement by facsimile transmission or other electronic transmission (such as .pdf or .tif) shall be effective as delivery of a manually signed counterpart of this Agreement.

[Remainder of page intentionally left blank]


BAUSCH HEALTH IRELAND LIMITED

By: 

Name: William N. Woodfield

Title: Director

BAUSCH+LOMB IRELAND LIMITED

By: 

Name: William N. Woodfield

Title: Director


SALIX PHARMACEUTICALS, INC.

By: 

Name: William N. Woodfield

Title: Vice President, Treasurer


BAUSCH & LOMB INCORPORATED

By: 

Name: William N. Woodfield

Title: Vice President, Treasurer


BAUSCH HEALTH US, LLC

By: 

Name: William N. Woodfield

Title: Senior Vice President, Treasurer

SOLTA MEDICAL, INC.

By:   
\_\_\_\_\_  
Name: William N. Woodfield  
Title: Director

SOLTA MEDICAL IRELAND LIMITED

By: \_\_\_\_\_  
Name: Jeremy Lipshy  
Title: Director

[Signature Page to IPSA – Barclays]

**PATENT**  
**REEL: 058205 FRAME: 0848**


SOLTA MEDICAL, INC.

By:

---

Name: William N. Woodfield  
Title: Director

SOLTA MEDICAL IRELAND LIMITED



By:

---

Name: Jeremy Lipshy  
Title: Director

Accepted and Agreed:

**BARCLAYS BANK PLC,**  
as Collateral Agent

By:

DocuSigned by:  
*Robert Walsh*  
FCDAF84F50AA411...

---

Name: Robert Walsh  
Title: Assistant Vice President

[Signature Page to IPSA – Barclays]

**PATENT**  
**REEL: 058205 FRAME: 0850**



**Schedule I - Trademark Collateral Schedule I - Trademark Collateral**

Current Owner on TMO Records	Mark Name	Current Application Number	Current Registration Number
BAUSCH + LOMB IRELAND LIMITED	IMMUNE DUO	90471068	N/A

**Schedule II – Patent Collateral**

Appl. No.	Publ. No.	Patent No.	Title	Current PTO Owner
17/207222	2021-0205406-A1		FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE	BAUSCH HEALTH IRELAND LIMITED
17/489939			PHARMACEUTICAL FORMULATIONS USEFUL FOR INHIBITING ACID SECRETION AND METHODS FOR MAKING AND USING THEM	SALIX PHARMACEUTICALS, INC.
63/243823			COMBINATIONS OF RIFAXIMIN AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER	BAUSCH HEALTH IRELAND LIMITED
63/239246			OPHTHALMIC DEVICES	BAUSCH + LOMB IRELAND LIMITED
17/462962			CONTACT LENS PACKAGING	BAUSCH + LOMB IRELAND LIMITED
63/239343			OPHTHALMIC DEVICES	BAUSCH + LOMB IRELAND LIMITED
63/239344			OPHTHALMIC DEVICES	BAUSCH + LOMB IRELAND LIMITED
17/398556			PACKAGING SOLUTIONS	BAUSCH + LOMB IRELAND LIMITED
17/397496			CONTACT LENS PACKAGING	BAUSCH & LOMB INCORPORATED
63/226614			METHODS FOR TREATING CONJUNCTIVITIS AND/OR COVID-19 USING BENZALKONIUM CHLORIDE	BAUSCH + LOMB IRELAND LIMITED
29/788730			LIGHT THERAPY DEVICE	SOLTA MEDICAL IRELAND LIMITED
17/366871	2021-0330681-A1		TOPICAL COMPOSITIONS AND METHODS FOR TREATING PSORIASIS	BAUSCH HEALTH US, LLC
17/365353			PHACOEMULSIFICATION HANDPIECE	BAUSCH + LOMB IRELAND LIMITED

None.

**Schedule III - Copyright Collateral**